Literature DB >> 10540091

Dosing study of remifentanil and propofol for tracheal intubation without the use of muscle relaxants.

R Alexander1, A J Olufolabi, J Booth, H E El-Moalem, P S Glass.   

Abstract

Sixty ASA I and II patients, premedicated with midazolam, were administered propofol 2 mg x kg-1 and remifentanil 3 microg x kg-1 (group R3), remifentanil 4 microg x kg-1 (group R4) and remifentanil 5 microg x kg-1 (group R5). Laryngoscopy and intubation were performed 1 min after the administration of the study drugs and the intubating conditions were assessed. Good to excellent conditions were observed in 12 patients in group R3 compared with 19 patients each in groups R4 and R5 (p = 0.004). Significant reductions in mean arterial pressure (MAP) and heart rate (HR) after administration of the study drug were observed in each group, p < 0.01. There was, however, no difference in mean MAP and HR between the three groups at all time points. We conclude that remifentanil 4-5 microg x kg-1 may reliably provide good to excellent conditions for tracheal intubation when administered after propofol 2 mg x kg-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10540091     DOI: 10.1046/j.1365-2044.1999.00904.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  22 in total

Review 1.  Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Stroke in Pregnancy: A Focused Update.

Authors:  Eliza C Miller; Lisa Leffert
Journal:  Anesth Analg       Date:  2020-04       Impact factor: 5.108

3.  Comparison of intubation conditions and apnea time after anesthesia induction with propofol/remifentanil combined with or without small dose of succinylcholine.

Authors:  Jing Jiao; Shaoqiang Huang; Yingjie Chen; Hailian Liu; Yi Xie
Journal:  Int J Clin Exp Med       Date:  2014-02-15

Review 4.  Spotlight on remifentanil for general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Comparison of intubating conditions with propofol suxamethonium versus propofol-LIDOCAINE.

Authors:  To Isesele; Fe Amadasun; Np Edomwonyi
Journal:  J West Afr Coll Surg       Date:  2012-10

Review 6.  Avoidance versus use of neuromuscular blocking agents for improving conditions during tracheal intubation or direct laryngoscopy in adults and adolescents.

Authors:  Lars H Lundstrøm; Christophe Hv Duez; Anders K Nørskov; Charlotte V Rosenstock; Jakob L Thomsen; Ann Merete Møller; Søren Strande; Jørn Wetterslev
Journal:  Cochrane Database Syst Rev       Date:  2017-05-17

7.  ED50 of remifentanil for providing excellent intubating conditions when co-administered with a single standard dose of propofol without the use of muscle relaxants in children: dose-finding clinical trial.

Authors:  Andre Hideo Ono; Thiago Rocha Moura; Cátia Sousa Govêia; Gabriel Magalhães Nunes Guimarães; Luís Cláudio de Araújo Ladeira; Helga Bezerra Gomes da Silva
Journal:  J Anesth       Date:  2018-05-04       Impact factor: 2.078

8.  Airway trauma in a high patient volume academic cardiac electrophysiology laboratory center.

Authors:  Zhe Yan; Jonathan W Tanner; David Lin; Ara A Chalian; Joseph S Savino; Lee A Fleisher; Renyu Liu
Journal:  Anesth Analg       Date:  2012-12-07       Impact factor: 5.108

9.  The effects of sevoflurane with propofol and remifentanil on tracheal intubation conditions without neuromuscular blocking agents.

Authors:  Wook Jong Kim; Seong Soo Choi; Doo Hwan Kim; Hye Jeong Seo; Eun Ha Suk; Seung Woo Ku; Pyung Hwan Park
Journal:  Korean J Anesthesiol       Date:  2010-08-20

10.  Priming with rocuronium or vecuronium prevents remifentanil-mediated muscle rigidity and difficult ventilation.

Authors:  Junya Nakada; Masao Nishira; Renko Hosoda; Kazumi Funaki; Shyunsaku Takahashi; Tatsuya Matsura; Yoshimi Inagaki
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.